|
|
Psoriasis Prime Time: The Role of TYK Inhibition in Psoriasis
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
In this edition of Psoriasis Prime Time, the faculty reviews the unique mechanism of action for allosteric tyrosine kinase 2 (TYK2) inhibitors compared with Janus kinase inhibito... |
|
|
Psoriasis With Scalp Involvement in a Patient With Skin of Color
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
This case will discuss the treatment of psoriasis in patients with skin of color, highlighting the challenges of treating scalp psoriasis. The faculty will review the mechanism o... |
|
|
Psoriasis Prime Time: TYK Inhibition in Hard-to-Treat Psoriasis
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
In this edition of Psoriasis Prime Time, the faculty reviews the use of allosteric tyrosine kinase 2 (TYK2) inhibitors in the treatment of hard-to-treat psoriasis, including the ... |
|
|
Patient Point of View: PDE4 Inhibitors for the Treatment of Adult Plaque Psoriasis
Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts affected individuals’ quality of life. The most common subtype is plaque psoriasis, characterized by erythematous to violaceous plaques covered with scales. Due to the substantial symptom burden of plaque psoriasis and challenges surrounding medication tolerability and adherence, innovative treatment options are needed. Phosphodiesterase-4 (PDE4) inhibitors, which play a key role in the inflammatory... |
|